Mometasone Furoate Delivered Via Breezhaler (R) And Twisthaler (R) In Patients With Asthma

Introduction: Mometasone furoate (MF), an inhaled corticosteroid (ICS), is approved for the treatment of asthma. Previous studies suggest that MF Twisthaler® doses of 800 and 200 µg and MF Breezhaler® doses of 320 and 80 µg would elicit similar lung function effects, respectively. These MF doses are also used in an indacaterol/MF combination in development for asthma. Since sensitivity to ICS is variable, individual patientsʼ ICS sensitivity (as measured by FEV1 decline on ICS weaning) was used to build a robust analysis model for the study data.